These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23532245)

  • 1. Evaluation of the Trial to Assess Chelation Therapy (TACT): the scientific process, peer review, and editorial scrutiny.
    Bauchner H; Fontanarosa PB; Golub RM
    JAMA; 2013 Mar; 309(12):1291-2. PubMed ID: 23532245
    [No Abstract]   [Full Text] [Related]  

  • 2. Concerns about reliability in the Trial to Assess Chelation Therapy (TACT).
    Nissen SE
    JAMA; 2013 Mar; 309(12):1293-4. PubMed ID: 23532246
    [No Abstract]   [Full Text] [Related]  

  • 3. Chelation therapy and cardiovascular outcomes.
    Kleinman B
    JAMA; 2013 Jul; 310(4):431. PubMed ID: 23917299
    [No Abstract]   [Full Text] [Related]  

  • 4. Chelation therapy and cardiovascular outcomes.
    Bittl JA
    JAMA; 2013 Jul; 310(4):430-1. PubMed ID: 23917297
    [No Abstract]   [Full Text] [Related]  

  • 5. Chelation therapy and cardiovascular outcomes--in reply.
    Lamas GA; Mark D; Lee KL
    JAMA; 2013 Jul; 310(4):431-2. PubMed ID: 23917300
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial.
    Lamas GA; Goertz C; Boineau R; Mark DB; Rozema T; Nahin RL; Lindblad L; Lewis EF; Drisko J; Lee KL;
    JAMA; 2013 Mar; 309(12):1241-50. PubMed ID: 23532240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT).
    Escolar E; Lamas GA; Mark DB; Boineau R; Goertz C; Rosenberg Y; Nahin RL; Ouyang P; Rozema T; Magaziner A; Nahas R; Lewis EF; Lindblad L; Lee KL
    Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):15-24. PubMed ID: 24254885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are concerns about reliability in the trial to assess chelation therapy fair grounds for a hasty dismissal?: An alternative perspective.
    Kaul S
    Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):5-7. PubMed ID: 24425709
    [No Abstract]   [Full Text] [Related]  

  • 9. Potential Role of Metal Chelation to Prevent the Cardiovascular Complications of Diabetes.
    Calderon Moreno R; Navas-Acien A; Escolar E; Nathan DM; Newman J; Schmedtje JF; Diaz D; Lamas GA; Fonseca V
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2931-2941. PubMed ID: 30869793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letter to the editor concerning article "Design of the Trial to Assess Chelation Therapy (TACT)".
    Ernst E
    Am Heart J; 2012 Dec; 164(6):e23; author reply e25. PubMed ID: 23194497
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT).
    Ujueta F; Arenas IA; Escolar E; Diaz D; Boineau R; Mark DB; Golden P; Lindblad L; Kim H; Lee KL; Lamas GA
    J Diabetes Complications; 2019 Jul; 33(7):490-494. PubMed ID: 31101487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From the National Heart, Lung, and Blood Institute (NHLBI): EDTA chelation therapy modestly reduces cardiovascular events.
    National Heart, Lung, and Blood Institute
    Ethn Dis; 2013; 23(3):388. PubMed ID: 23914432
    [No Abstract]   [Full Text] [Related]  

  • 13. Design of the Trial to Assess Chelation Therapy (TACT).
    Lamas GA; Goertz C; Boineau R; Mark DB; Rozema T; Nahin RL; Drisko JA; Lee KL
    Am Heart J; 2012 Jan; 163(1):7-12. PubMed ID: 22172430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiology Patient Page. Chelation therapy: a new look at an old treatment for heart disease, particularly in diabetics.
    Lamas GA
    Circulation; 2015 May; 131(21):e505-6. PubMed ID: 26015468
    [No Abstract]   [Full Text] [Related]  

  • 15. Chelation therapy in cardiovascular disease: an update.
    Sultan S; Murarka S; Jahangir A; Mookadam F; Tajik AJ; Jahangir A
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):843-854. PubMed ID: 28597699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chelation therapy is TACT-less.
    Jackson G
    Int J Clin Pract; 2008 Dec; 62(12):1821-2. PubMed ID: 19166425
    [No Abstract]   [Full Text] [Related]  

  • 17. Chelation trial in patients with cardiovascular disease.
    Yen TH; Yen JS
    Am Heart J; 2023 Feb; 256():1. PubMed ID: 36336079
    [No Abstract]   [Full Text] [Related]  

  • 18. EDTA Chelation Therapy to Reduce Cardiovascular Events in Persons with Diabetes.
    Ouyang P; Gottlieb SH; Culotta VL; Navas-Acien A
    Curr Cardiol Rep; 2015 Nov; 17(11):96. PubMed ID: 26364188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why the NIH Trial to Assess Chelation Therapy (TACT) should be abandoned.
    Atwood KC; Woeckner E; Baratz RS; Sampson WI
    Medscape J Med; 2008 May; 10(5):115. PubMed ID: 18596934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chelation therapy to treat atherosclerosis, particularly in diabetes: is it time to reconsider?
    Lamas GA; Ergui I
    Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):927-38. PubMed ID: 27149141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.